Naproxen/Esomeprazole Fixed-Dose Combination
Author:
- 1 March 2011
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 28 (3) , 237-248
Abstract
Naproxen/esomeprazole is a fixed-dose combination of the NSAID naproxen and the proton pump inhibitor esomeprazole. In two well designed, 12-week studies, naproxen/esomeprazole fixed-dose combination was noninferior to celecoxib in treating the signs and symptoms of disease in patients with osteoarthritis of the knee, as assessed by the mean change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index pain and function scores and Patient Global Assessment scores (coprimary endpoints). Two other studies showed that the cumulative incidence of gastric ulcers (primary efficacy measure) was significantly lower with naproxen/esomeprazole than with enteric-coated naproxen alone during up to 6 months’ therapy in patients with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or any other condition requiring daily NSAID therapy. The fixed-dose combination was generally well tolerated in these studies, with an upper gastrointestinal tolerability profile generally better than that of naproxen and similar to that of celecoxib.Keywords
This publication has 21 references indexed in Scilit:
- Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy volunteersAlimentary Pharmacology & Therapeutics, 2010
- Clinical trial: the incidence of NSAID‐associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric‐coated naproxen aloneAlimentary Pharmacology & Therapeutics, 2010
- Methotrexate Drug Interactions in the Treatment of Rheumatoid Arthritis: A Systematic ReviewThe Journal of Rheumatology, 2010
- OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis and Cartilage, 2008
- Clinical Efficacy of Esomeprazole in the Prevention and Healing of Gastrointestinal Toxicity Associated with NSAIDs in Elderly PatientsDrugs & Aging, 2008
- EsomeprazoleDrugs, 2008
- Summing the risk of NSAID therapyThe Lancet, 2007
- NSAID-Associated Adverse Effects and Acid Control Aids to Prevent ThemDrug Safety, 2006
- Naproxen A Reappraisal of its Pharmacology, and Therapeutic Use in Rheumatic Diseases and Pain StatesDrugs, 1990
- NaproxenDrugs, 1975